slides · global inventory
Resolution
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,534
Current window 22,951-22,980
Pages 1,418
Rows per page 30
Beat
22,951-22,980 of 42,534
31
The slide uses a numbered process flow (1-5) to explain a molecular biology mechanism.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
32
The slide shows immunohistochemistry images (NeuN, myc, DAPI, merge) for two experimental conditions across two mouse IDs each.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
33
The slide displays immunofluorescence staining (NeuN, myc, DAPI, merge) across three brain regions (Thalamus, Hippocampus, Brain Stem) for two treatment groups (PHP.B/mini vs PHP.B/mini-miRARE).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
34
The chart shows survival rates over 35 weeks for various dosage groups of AAV9/MECP2 and TSHA-102.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
35
The slide compares TSHA-102 against control and other AAV9 constructs. The bottom box highlights specific adverse event rates (lesions/prolapses).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
36
The chart shows survival percentages over time (weeks) for different treatment groups, with diamonds indicating vet-requested euthanasia.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
37
Taysha | IPO Presentation Deck | 66 slidesTaysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
38
The slide uses a consistent structure for each pipeline asset: program name, target indication, development stage, disease description, and prevalence.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
39
The background features a DNA gel electrophoresis image, reinforcing the genetic theme.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
40
The slide uses a list-based structure to detail the mechanism, clinical impact, and prevalence for each pipeline asset.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
41
The slide highlights infrastructure capabilities, specifically listing Sartorius equipment and color-coded floor plan areas.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
42
The slide includes a footnote clarifying the cash position as of June 30, 2020, adjusted for subsequent financing.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
43
The slide uses a T-shaped graphic as a visual anchor, likely referencing the company's branding or a 'T' for 'Timeline'.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
44
Taysha | IPO Presentation Deck | 66 slidesTaysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
45
The image is a classic representation of DNA sequencing or fingerprinting, often used in biotech pitch decks to signify core proprietary technology.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
46
The diagram illustrates a molecular biology workflow for AAV capsid engineering.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
47
The slide highlights the potential to bypass immune responses for gene therapy redosing.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
48
Includes a disclaimer about intellectual property rights at the bottom.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
49
The slide uses a numbered process flow (1-5) to explain a biological mechanism.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
50
The slide outlines a specific R&D process (Reg1 and MiRARE) for gene therapy target identification.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
51
The slide highlights a specific 'miRARE' target panel derived from the data analysis.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
52
The background features a gel electrophoresis image, common in biotech/genomics pitch decks.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
53
The chart is a box-and-whisker plot comparing age of onset, death, and last report across multiple genetic conditions, highlighting SURF1.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
54
Includes a molecular diagram of glycogen branching and a therapeutic component breakdown (AAV9 + hGBE1 + Intrathecal delivery).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
55
Includes a bar chart of EPM2A/EPM2B cases by country and a biological process diagram showing the transition from glycogen to Lafora bodies.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
56
Includes a scientific diagram of glycogen branching and a bar chart showing Gys1 deficiency impact.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
57
The slide uses Kaplan-Meier survival curves and longitudinal body mass measurements to validate the therapeutic hypothesis.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
58
Includes a visual representation of MAPT mutations linked to specific FTLD-tau subtypes and a process diagram of tau aggregation.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
59
The background image is a DNA gel electrophoresis, suggesting a biotech or genetic research context.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
60
Includes a visual mechanism of action diagram showing the silencing of Ube3a-ATS to restore Ube3a expression.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit